Lunsekimig
- Generic Name
- Lunsekimig
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- First Posted Date
- 2025-04-07
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06914908
- Locations
- 🇺🇸
Modena Allergy + Asthma- Site Number : 8400005, La Jolla, California, United States
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 144
- Registration Number
- NCT06790121
- Locations
- 🇺🇸
T. Joseph Raoof MD Inc-Site Number: 8400004, Encino, California, United States
🇺🇸Clinical Trials Research Institute-Site Number: 8400003, Thousand Oaks, California, United States
🇯🇵Investigational Site Number: 3920005, Asahikawa-shi, Japan
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- Conditions
- Asthma
- Interventions
- Drug: Short-Acting Beta Agonists (SABA)Drug: PlaceboDrug: Fluticasone/salmeterolDrug: Budesonide/formoterol
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1000
- Registration Number
- NCT06676319
- Locations
- 🇺🇸
Chandler Clinical Research Trials- Site Number : 8400075, Chandler, Arizona, United States
🇺🇸Epic Medical Research - Surprise- Site Number : 8400052, Surprise, Arizona, United States
🇺🇸Tucson Clinical Research Institute - Site number: 8400085, Tucson, Arizona, United States
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 530
- Registration Number
- NCT06609239
- Locations
- 🇺🇸
Allianz Research Institute CO- Site Number : 8400026, Aurora, Colorado, United States
🇺🇸Western States Clinical Research- Site Number : 8400014, Wheat Ridge, Colorado, United States
🇺🇸Qway Research - Hialeah- Site Number : 8400015, Hialeah, Florida, United States
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: placebo
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 80
- Registration Number
- NCT06454240
- Locations
- 🇺🇸
Modena Allergy + Asthma Site Number : 8400005, La Jolla, California, United States
🇺🇸United Gastroenterologists - Murrieta- Site Number : 8400021, Murrieta, California, United States
🇺🇸Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003, Roseville, California, United States
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 685
- Registration Number
- NCT06102005
- Locations
- 🇨🇳
Investigational Site Number : 1560013, Shanghai, China
🇨🇳Investigational Site Number : 1560015, Shenyang, China
🇨🇳Investigational Site Number : 1560005, Wenzhou, China
First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT05366764
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
🇬🇧Investigational Site Number : 8260001, Belfast, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.